Drugs used to treat type 2 diabetes Mounjaro VS Ozempic were compared in an analysis of 22 studies. Although only marginally better, Mounjaro was also superior in terms of weight loss and blood sugar control.
In a study of two medications for type 2 diabetes, tirzepatide (Mounjaro) was found to be more effective than semaglutide (Ozempic) at regulating blood sugar (glucose) and encouraging weight loss.
Early October will see the presentation of the meta-analysis of 22 randomized controlled trials at the European Association for the Study of Diabetes (EASD) annual meeting.
A peer-reviewed journal has not yet published the study.
Here are some important facts concerning these medications’ comparisons.
Drugs imitate hormones(mounjaro vs ozempic)
Also read-Five Things To Focus On For Losing Weight After Pregnancy
A group of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists includes semaglutide. It imitates the GLP-1 hormone, which after eating is secreted in the gut.
The hormone GLP-1 and another hormone produced after eating, the glucose-dependent insulinotropic polypeptide (GIP), are both mimicked by tirzepatide.
According to several research, tirzepatideTrusted Source’s dual actions make it more successful than single-acting medications like semaglutide for controlling blood sugar levels and promoting weight loss.
Only studies that examined the subcutaneously administered injectable versions of semaglutide and tirzepatide were included in the latest meta-analysis.
The SURPASS-2 experiment and another smaller study were two of the 22 trials that were a part of the meta-analysis that directly compared semaglutide with tirzepatide(mounjaro vs ozempic)
Twenty other trials compared semaglutide or tirzepatide with a standard comparator, such as a basal insulin dose, an inert placebo, or other GLP-1 receptor agonist medications. Indirect comparisons between semaglutide and tirzepatide were made using these studies.
Data from 18,472 patients with a diagnosis of type 2 diabetes were totaled throughout the investigations.
The studies looked at semaglutide at 0.5, 1.0, or 2.0 milligrams and once-weekly maintenance dosages of tirzepatide at 5, 10, or 15 mg. At least a 12-week study period was used.
Other names for semaglutide include Wegovy, an injectable medication for obesity, and Rybelsus, an oral medication for type 2 diabetes.
The use of tirzepatide as an anti-obesity medication is still not authorized in the US.
Blood sugar is decreased(mounjaro vs ozempic)
mounjaro vs ozempic
The highest reduction in blood sugar was seen with the 15-milligram dose of tirzepatide, which reduced HbA1c by an average of 2% when compared to a placebo.
Both tirzepatide 10 mg and semaglutide 2.0 mg reduced HbA1c on average by 1.86% and 1.62%, respectively.
A blood test called HbA1c is performed to check how well diabetics are controlling their blood sugar levels.
Researchers discovered that each dose of tirzepatide reduced HbA1c more than the corresponding low, medium, and high doses of semaglutide.
The National Institute for Health and Care Excellence defines “clinically important” as a decrease in HbA1c of at least 0.5%.Reliable Source
Body weight loss(mounjaro vs ozempic)
Reductions in body weight were greatest with tirzepatide, when compared to placebo: 24.2 pounds for the high dose, 19.3 pounds for the medium dose, and 13.6 pounds for the low dose, on average.
In contrast, people taking semaglutide lost an average of 11.6 pounds on the high dose, 9.8 pounds on the medium dose, and 6 pounds on the low dose.
When the two drugs were compared directly, the high and medium doses of tirzepatide resulted in more weight loss than all three doses of semaglutide.
The low dose of tirzepatide was more effective for weight loss than the medium and low doses of semaglutide.
Negative consequences
All doses of semaglutide and tirzepatide increased the risk of nausea, vomiting and diarrhea compared to placebo. The highest dose of tirzepatide was associated with the greatest increased risk of these gastrointestinal side effects.
The highest dose of tirzepatide also had a greater risk of vomiting than the medium and low doses of semaglutide, and a greater risk of nausea than the low dose of semaglutide.
There were no significant differences between the two drugs and placebo for the risk of serious adverse events.
weighing the costs, risks, and advantages
In terms of deciding which drug to use for the treatment of type 2 diabetes, Cheng recommends that people talk with their doctor about the risks and benefits of each medication.
However, while clinical trials provide an overview of the average rates of side effects experienced by people, individuals may have a different experience with some drugs.
In her clinic, Messer’s patients tend to tolerate tirzepatide better than semaglutide. In addition, she said constipation is usually more of a concern than diarrhea for people taking these drugs.
Cost might also influence people’s choices. According to a recent study, the total cost of 72 weeks of tirzepatide was $17, 527 as opposed to $22, 878 for 68 weeks of semaglutide. In addition, if a prescription is prescribed off-label, a person’s insurance may not pay for the cost of the medication.
The FDA has received an application from Eli Lilly for the use of tirzepatide in the treatment of persistent obesity, the company reported in August.
Messer stated that patients paying out of pocket may benefit from this drug’s FDA approval.
“We have a lot of patients who don’t have diabetes, but are paying out of pocket [for tirzepatide], using coupons to cover the cost, and doing whatever they can to get hold of it,” she said.
Takeaway
A meta-analysis of 22 studies compared tirzepatide (Mounjaro) and semaglutide (Ozempic), drugs used to treat type 2 diabetes. Tirzepatide was superior for blood sugar control, although only slightly, and also for weight loss.
Certain side effects were greater with tirzepatide, including vomiting and nausea. Experts say it is important to consider these side effects when deciding which drug to use.
Tirzepatide is not yet approved in the United States for obesity, but can be prescribed off-label for that purpose. Earlier this year, though, the drug was facing shortages due to high demand.
Also read-Five Things To Focus On For Losing Weight After Pregnancy
images source-google
